Sugi Predict

Sugi Predict / Compounds / SCHEMBL19748092

SCHEMBL19748092

SCHEMBL19748092

Cc1c(F)cc(S(=O)(=O)NCC(C)(C)O)cc1Br

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 1/20 0.40
▸ IKBKB O14920 1/20 0.39
▸ CHUK O15111 1/20 0.39
▸ CYP2C19 P33261 1/20 0.38
▸ ALOX5AP P20292 2/20 0.37
▸ FEN1 P39748 2/20 0.37
▸ PIK3CG P48736 11/20 0.36
▸ PIK3CD O00329 8/20 0.36
▸ PIK3CB P42338 6/20 0.36
▸ NEK1 Q96PY6 1/20 0.36
▸ PIK3CA P42336 6/20 0.35
▸ CA12 O43570 2/20 0.35
▸ CA1 P00915 2/20 0.35
▸ CA2 P00918 2/20 0.35
▸ CA9 Q16790 2/20 0.35
▸ MTOR P42345 2/20 0.35
▸ PIK3C3 Q8NEB9 1/20 0.35
▸ PIK3R2 O00459 1/20 0.35
▸ PIK3R1 P27986 1/20 0.35
▸ PIK3R3 Q92569 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19747722 0.91 ALDH1A1 (0.38) ALDH1A1IKBKBCHUKCYP2C19ALOX5AP
SCHEMBL20940189 0.83 ALDH1A1 (0.38) ALDH1A1IKBKBCHUKCYP2C19ALOX5AP
SCHEMBL17203142 0.77 PIK3CG (0.48) IKBKBCHUKPIK3CGPIK3CDPIK3CB
SCHEMBL19747511 0.76 IKBKB (0.35) ALDH1A1IKBKBCHUKCYP2C19ALOX5AP
SCHEMBL17203037 0.76 PIK3CG (0.46) ALDH1A1IKBKBCHUKCYP2C19ALOX5AP
SCHEMBL17203853 0.76 PIK3CG (0.47) ALDH1A1IKBKBCHUKCYP2C19ALOX5AP
SCHEMBL17203800 0.75 IKBKB (0.44) IKBKBCHUKPIK3CGPIK3CDPIK3CB
SCHEMBL17204003 0.73 KMT2A (0.51) ALDH1A1IKBKBCHUKCYP2C19PIK3CG
SCHEMBL17204198 0.71 ALDH1A1 (0.53) ALDH1A1IKBKBCHUKPIK3CGPIK3CD
SCHEMBL17204017 0.71 IKBKB (0.41) IKBKBCHUKPIK3CGPIK3CDPIK3CB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12030885-B2 Substituted imidazo[2,1-f][1,2,4]triazines as PI3K-gamma inhibitors INCYTE CORPORATION (US) 2024-07-09 — — US disclosed
US-20220251087-A1 HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS INCYTE CORPORATION 2022-08-11 — — US disclosed
US-10975088-B2 Imidazo[2,1-f][1,2,4]triazine compounds as pi3k-y inhibitors INCYTE CORPORATION (US) 2021-04-13 — — US disclosed
US-10975088-B2 Imidazo[2,1-f][1,2,4]triazine compounds as pi3k-y inhibitors INCYTE CORPORATION (US) 2021-04-13 — — US disclosed
US-20200102315-A1 HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS INCYTE CORPORATION 2020-04-02 — — US disclosed
US-10479795-B2 Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines and substituted imidazo[1,2-b]pyridazines as PI3K-gamma inhibitors INCYTE CORPORATION (US) 2019-11-19 — — US disclosed
US-10479795-B2 Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines and substituted imidazo[1,2-b]pyridazines as PI3K-gamma inhibitors INCYTE CORPORATION (US) 2019-11-19 — — US disclosed
US-20190119287-A1 HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS INCYTE CORPORATION 2019-04-25 — — US disclosed
US-20190119287-A1 HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS INCYTE CORPORATION 2019-04-25 — — US disclosed
US-10138248-B2 Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-b]pyridazines and substituted imidazo[1,2-a]pyrazines as PI3K-γ inhibitors INCYTE CORPORATION (US) 2018-11-27 — — US disclosed
US-20180009816-A1 HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS INCYTE CORPORATION 2018-01-11 — — US disclosed
US-20180009816-A1 HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS INCYTE CORPORATION 2018-01-11 — — US disclosed
WO-2017223414-A1 HETEROCYCLIC COMPOUNDS AS PI3K-γ INHIBITORS INCYTE CORPORATION (US) 2017-12-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10479795-B2 Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines and substituted imidazo[1,2-b]pyridazines as PI3K-gamma inhibitors PIK3CG, PIK3CD, PIK3CA ALDH1A1 1354/4885IKBKB 157/4885CHUK 60/4885
US-12030885-B2 Substituted imidazo[2,1-f][1,2,4]triazines as PI3K-gamma inhibitors PIK3CG, PIK3CD, PIK3R5 ALDH1A1 1774/4885IKBKB 109/4885CHUK 42/4885
US-20200102315-A1 HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS PIK3R5, PIK3CA, PIK3CD ALDH1A1 3638/4885IKBKB 50/4885CHUK 34/4885
US-10138248-B2 Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-b]pyridazines and substituted imidazo[1,2-a]pyrazines as PI3K-γ inhibitors PIK3CA, PIK3CG, PIK3CD ALDH1A1 1168/4885IKBKB 208/4885CHUK 62/4885
US-10975088-B2 Imidazo[2,1-f][1,2,4]triazine compounds as pi3k-y inhibitors PIK3R5, PIK3CD, PIK3CA ALDH1A1 2818/4885IKBKB 108/4885CHUK 47/4885
US-20190119287-A1 HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS PIK3R5, PIK3CA, PIK3CD ALDH1A1 3638/4885IKBKB 50/4885CHUK 34/4885
US-20180009816-A1 HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS PIK3R5, PIK3CA, PIK3CD ALDH1A1 3638/4885IKBKB 50/4885CHUK 34/4885
US-20220251087-A1 HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS PIK3R5, PIK3CA, PIK3CD ALDH1A1 3638/4885IKBKB 50/4885CHUK 34/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.